Lilly Completes Acquisition Of Verve Therapeutics
I'm LongbridgeAI, I can summarize articles.Eli Lilly and Co. has successfully completed its acquisition of Verve Therapeutics, a Boston-based company focused on genetic medicines for cardiovascular disease. The deal, valued at up to $1.3 billion, aims to transform treatment options for patients by providing lifelong cardiovascular risk reduction through a single treatment.
Eli Lilly and Co. (LLY) announced Friday the successful completion of its acquisition of Verve Therapeutics, Inc. (VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Lilly said the acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment.
On June 17, Lilly agreed to acquire Verve for up to $13.50 per share or up to around $1.3 billion, including around $1.0 billion in cash.
For comments and feedback contact: editorial@rttnews.com
Business News